These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15251123)

  • 41. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
    Martin JH; Potthoff A; Ledig S; Cornberg M; Jandl O; Manns MP; Kubicka S; Flemming P; Athmann C; Beil W; Wagner S
    Helicobacter; 2004 Oct; 9(5):371-86. PubMed ID: 15361075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
    Mollinedo F; Gajate C
    Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
    Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Shirwan H; Yaniv I; Askenasy N
    Exp Hematol; 2007 Oct; 35(10):1601-12. PubMed ID: 17889725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
    Zhang J; Xu G
    Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells.
    Kang YH; Lee KA; Ryu CJ; Lee HG; Lim JS; Park SN; Paik SG; Yoon DY
    Cancer Lett; 2006 Jun; 237(1):33-44. PubMed ID: 16019139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the Fas/FasL signaling pathway in cancer therapy.
    Villa-Morales M; Fernández-Piqueras J
    Expert Opin Ther Targets; 2012 Jan; 16(1):85-101. PubMed ID: 22239437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of CD95L expression on tumor rejection in mice.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Fas-FasL in insulitis in nonobese diabetic mouse.
    Cao JY; Wang H
    Chin Med J (Engl); 2004 Apr; 117(4):615-7. PubMed ID: 15109461
    [No Abstract]   [Full Text] [Related]  

  • 50. Significance of tumor-cell receptors in human cancer.
    Zeromski J
    Arch Immunol Ther Exp (Warsz); 2002; 50(2):105-10. PubMed ID: 12022699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Fas/Fas ligand system and cancer: immune privilege and apoptosis.
    Abrahams VM; Kamsteeg M; Mor G
    Mol Biotechnol; 2003 Sep; 25(1):19-30. PubMed ID: 13679631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor counterattack--concept and reality.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2000 Mar; 30(3):725-31. PubMed ID: 10741386
    [No Abstract]   [Full Text] [Related]  

  • 53. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
    Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition.
    French LE; Tschopp J
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1656-61. PubMed ID: 11103436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of FasL and Fas in health and disease.
    Ehrenschwender M; Wajant H
    Adv Exp Med Biol; 2009; 647():64-93. PubMed ID: 19760067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apoptosis in oncology.
    Fan XQ; Guo YJ
    Cell Res; 2001 Mar; 11(1):1-7. PubMed ID: 11305320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.
    Sträter J; Möller P
    Virchows Arch; 2003 Mar; 442(3):218-25. PubMed ID: 12647210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does CD95 have tumor promoting activities?
    Peter ME; Legembre P; Barnhart BC
    Biochim Biophys Acta; 2005 May; 1755(1):25-36. PubMed ID: 15907590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fas counter-attack--the best form of tumor defense?
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Nat Med; 1999 Mar; 5(3):267-8. PubMed ID: 10086376
    [No Abstract]   [Full Text] [Related]  

  • 60. Fas-ligand mediated apoptosis in severe sepsis and shock.
    Ayala A; Lomas JL; Grutkoski PS; Chung S
    Scand J Infect Dis; 2003; 35(9):593-600. PubMed ID: 14620140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.